Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: Imidazo[4,5-c]quinoline compounds of Formula (I) having a substituent that is attached at the N?1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: Imidazoquinoline compounds, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods of use of such compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals.

Abstract: Phosphate-containing copolymers, medical compositions containing the phosphate-containing copolymers, and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. The phosphate-containing copolymers are prepared by phosphorylating either a random copolymer or a random copolymeric block that contains monomeric units of propylene oxide and glycidol.

Abstract: Imidazoquinoline compounds, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods of use of such compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals.

Abstract: Compositions that include from 0.1 wt-% to 8 wt-% of one or more compounds of formula (I) based on the total weight of the composition HOCH2—(CHOH)n—CH2NR1R2??(I) wherein R1 and R2 are independently selected from the group consisting of a hydrogen atom, an alkyl group, C(O)R3, and SO2R4; with R3 and R4 being independently selected from the group consisting of an alkyl group, an aryl group, and an aralkyl group; wherein n is an integer from about 2 to about 5; from 5 wt-% to 95 wt-% of one or more plant based oils based on the total weight of the composition; from 5 wt-% to 80 wt-% water based on the total weight of the composition and from 0.01 wt-% to 1 wt-% of one or more nonionic aromatic phenolic preservatives based on the total weight of the composition wherein the composition has a pH from 4.5 to 9.5, the composition is an emulsion, and the composition is edible.

Abstract: Compositions that include: from 5 wt-% to 30 wt-% of one or more plant based oils based on the total weight of the composition; from 70 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; from 0.1 wt-% to 5 wt-% of one or more surfactants based on the total weight of the composition; and from 0.05 wt-% to 3 wt-% of a viscosity modifier, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.

Abstract: Medical compositions and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. More specifically, the medical compositions include a phosphonate-containing polymer. The phosphonate-containing polymers can suppress the expression of various virulence factors without destroying all microbes that may be present.

Abstract: Compositions that include: from 5 wt-% to 70 wt-% of one or more plant based oils based on the total weight of the composition; from 35 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; not greater than 7.5 wt-% of one or more surfactants based on the total weight of the composition; and not greater than 3 wt-% of a viscosity modifier of, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.

Abstract: A method of making a nonwoven fiber web comprises: providing a melt-blown nonwoven fiber web comprising bonded primary fibers having an average fiber diameter of 2 to 100 microns, wherein the primary fibers comprise a copolymer comprising divalent hydroxyethylene monomer units and divalent dihydroxybutylene monomer units; opening at least a portion of the melt-blown nonwoven fiber web to provide loose primary fibers; combining the loose primary fibers with secondary fibers; and forming a secondary nonwoven fiber web comprising the primary fibers and secondary fibers. A fiber web preparable according to the method and a multicomponent fiber including a first phase comprising a copolymer comprising divalent hydroxyethylene monomer units and divalent dihydroxybutylene monomer units and a second phase comprising a non-biodegradable polymer.

Abstract: A composition comprising from 1 wt-% to 3 wt-% total of glucosamine a derivative of glucosamine, or a combination thereof based on the total weight of the composition, and from 0.3 wt-% to 3 wt-% total of one or more surfactants, based on the total weight of the composition, of Formula (I): HOCH2—(OHOH)n—CH2NR1R2 (I) wherein R1 and R2 are independently selected from the group consisting of a hydrogen atom, an alkyl group, C(O)R3 and SO2R4 with R3 and R4 being independently selected from the group consisting of an alkyl group, an aryl group and an aralkyl group, wherein n is an integer from 2 to 5.

Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: A composition comprising: from 0.2 wt-% to 3 wt-% total of arginine, glycine, or a combination thereof based on the total weight of the composition; and from 0.3 wt-% to 3 wt-% total of one or more surfactants, based on the total weight of the composition, of Formula I: HOCH2—(CHOH)n—CH2NR1R2 (I) wherein R1 and R2 are independently selected from the group consisting of a hydrogen atom, an alkyl group, C(O)R3, and SO2R4; with R3 and R4 being independently selected from the group consisting of an alkyl group, an aryl group, and an aralkyl group; wherein n is an integer from about 2 to about 5.

Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing (or inhibiting) cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: Compositions that include: from 5 wt-% to 70 wt-% of one or more plant based oils based on the total weight of the composition; from 35 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; not greater than 7.5 wt-% of one or more surfactants based on the total weight of the composition; and not greater than 3 wt-% of a viscosity modifier of, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.

Abstract: Articles that include not greater than 60 wt-% of one or more plant based oil that is solid at 25° C. (room temperature), the weight percent based on the total weight of the article; and from 4 wt-% to 10 wt-% of gelatin, from 0.8 to 5 wt-% of agar, or a combination thereof, the weight percent based on the total weight of the article, wherein the article is solid set and homogeneous. Methods of using the articles and compositions for forming the articles are also disclosed.

Abstract: Articles that include from 70 wt-% to 99 wt-% of one or more plant based oil that is solid at 25° C., the weight percent based on the total weight of the article; and from 0.5 wt-% to 10 wt-% of fumed silica, the weight percent based on the total weight of the article. Methods of use of the articles are also included.

Abstract: Articles that include from 20 wt-% to 45 wt-% of one or more plant based oils based on the total weight of the article; from 50 wt-% to 70 wt-% of one or more polymer film formers based on the total weight of the article; and from 5 wt-% to 15 wt-% of one or more humectants based on the total weight of the article. Further articles comprises this combination of oil, film former and humectant as a first layer adjacent to which a second layer comprises a mucoadhesive polymer. The articles may be used to prevent formation or maintenance of biofilm in an oral tissue, affect hydration loss in an oral tissue, affect lubricity or lubriciousness in an oral tissue or treat xerostomia or dry mouth. Preferred polymer film formers include pullulan, xanthan gum, HP guar, ethyl cellulose and carrageenan.

Abstract: Imidazo[4,5-c]quinoline compounds of Formula (I) having a substituent that is attached at the N?1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: A copolymer composition that includes a silicone copolymer, methods of making the composition, and articles that include the composition, wherein the copolymer composition includes a silicone copolymer having a backbone composition that includes: silicone segments in an amount of 5 wt-% to 40 wt-%, based on the total weight of the silicone copolymer; hydrophilic segments in an amount of 40 wt-% to 75 wt-%, based on the total weight of the silicone copolymer; and reinforcing segments in an amount of 5 wt-% to 30 wt-%, based on the total weight of the silicone copolymer, wherein the reinforcing segments are derived from the reaction of one or more chain extenders with one or more multi-functional isocyanates, multi-functional carboxylic acids, multi-functional anhydrides, multi-functional esters, and/or multi-functional acid halides; wherein the silicone segments, hydrophilic segments, and reinforcing segments are connected through urea, urethane, amide, and/or oxamide linkages; wherein the hydrophilic segments